GlassScriptPhysician profile
Bruce W Arthur
NPI 1205956018
$3,982.06
in general payments reported to CMS, 2019-2025
34 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $678 · 2021: $795 · 2022: $716 · 2023: $727 · 2024: $223 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.84 |
| Education | $118.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $620.90 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $402.51 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Grifols USA, LLC | $358.01 | 2019-2023 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $268.71 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.61 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Genzyme Corporation | $199.48 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $169.34 | 2019-2023 | Opsumit |
| Teva Pharmaceuticals USA, INC. | $140.71 | 2021-2022 | |
| Integra Lifesciences Corporation | $121.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $118.79 | 2023-2025 | |
| Pfizer INC. | $115.34 | 2019-2023 | |
| Genentech USA, INC. | $113.92 | 2020-2024 | Xolair |
| Janssen Pharmaceuticals, INC | $110.20 | 2019-2024 | Xarelto |
| Philips North America LLC | $109.95 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $107.95 | 2020-2023 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $107.40 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $102.88 | 2019-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $87.81 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $79.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.08 | 2020-2022 | |
| Mylan Specialty L.P. | $62.84 | 2019-2022 | |
| United Therapeutics Corporation | $47.72 | 2023 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $36.37 | 2022 | |
| Shionogi INC | $32.03 | 2022 | |
| Electromed, INC. | $29.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.47 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.70 | 2021-2023 | Acthar |
| Baxter Healthcare | $18.57 | 2023 | Hillrom - Life 2000 Ventilation System |
| Siemens Medical Solutions USA, INC. | $15.87 | 2021 | |
| Ekos Corporation | $15.21 | 2019 | |
| Vapotherm INC | $13.99 | 2020 | |
| Resmed Corp | $13.42 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.94 | 2021 | |
| Shire North American Group INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.